Navigation Links
Intestinal protein may have role in ADHD, other neurological disorders
Date:8/12/2011

CINCINNATI A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD (Attention Deficit Hyperactivity Disorder) other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

Scientists have for the last quarter century studied the intestinal membrane receptor protein, guanylyl cyclase-C (GC-C) for its role in diarrheal disease and other intestinal functions, according to Mitchell Cohen, M.D., U.S. author on the study and director of Gastroenterology, Hepatology and Nutrition at Cincinnati Children's Hospital Medical Center. In fact, it had been thought that GC-C was found primarily in the intestine.

In the current study, scientists in China who collaborated with Dr. Cohen discovered that the receptor is also expressed in critical areas of the brain. The senior author on the study is Dr. Minmin Luo, a researcher at the National Institute of Biological Sciences and Tsinghua University in Beijing.

Using a mouse model developed in Dr. Ralph Giannella's laboratory at the University of Cincinnati, in which the GC-C receptor is deleted, or knocked out, the researchers found the mice exhibit hyperactivity and attention deficits. It is the first time that GC-C has been linked to neuropsychiatric disorder, according to the researchers.

"We show that the neurons selectively express GC-C and that its activation amplifies the excitatory responses mediated by other receptors on dopamine neurons in the midbrain," said Dr. Luo. "Working through a protein kinase called PKG, GC-C activity increases brain dopamine levels and thus regulate mouse attention and activity level."

When the researchers treated the GC-C knockout mice with amphetamine-based ADHD medication and a PKG activator, it reversed their hyperactive, inattentive behavior.

"The results indicate important behavioral and physiological functions for the GC-C/PKG signaling pathway in the brain," said Dr. Luo. "The data also suggest new therapeutic targets for neuropsychiatric disorders related to malfunctions of midbrain dopamine receptors."

One of the most prevalent human behavioral disorders, ADHD has been linked to imbalances in the dopamine system. The researchers noted in the study that its findings mice exhibiting reduced dopamine levels and related behavioral problems are consistent with the biochemical characteristics of human ADHD.

"This could make the GC-C knockout mouse a good research model for ADHD and other behavioral disorders," said Dr. Cohen. "Efforts to develop activators or inhibitors of the GC-C/PKG signaling pathway may lead to novel treatments for other disorders, such schizophrenia, Parkinson's disease and addiction."


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related biology technology :

1. New screening techniques, treatments shed light on gastrointestinal disorders in children
2. FDA Grants Fast Track Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
3. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
4. NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
7. Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohns Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
8. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
9. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
10. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
11. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... WARRINGTON, Pa. , Feb. 3, 2016 /PRNewswire/ ... biotechnology company focused on developing aerosolized KL4 surfactant ... Board of Directors has approved an inducement award ... Craig Fraser , its newly appointed President and ... the Board,s Compensation Committee on February 1, 2016 ...
(Date:2/3/2016)... 2016 Ascendis Pharma A/S (Nasdaq: ASND ... innovative TransCon technology to address significant unmet medical needs, ... conference.Event:2016 Leerink Partners Global Healthcare Conference Location: , ... 10, 2016 Time:  , 11:55am EST ... An audio webcast of this event will be ...
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences ... targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s ... therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid beta target ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of a new ... Las Vegas , where Joey appeared at the ... Las Vegas , where Joey appeared at the Wocket booth to ... was filmed at the Consumer Electronics Show (CES2016) in Las ... and greet fans. --> --> ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
Breaking Biology News(10 mins):